One of the latest Labs/Clients to join the MOMS network is Veravas. The lab is transforming the future of laboratory diagnostics through proprietary patented technology, VeraBIND™, designed to overcome long-standing challenges in the industry by eliminating interfaces and accurately detecting low-abundance biomarkers, resulting in early detection and improved outcomes.
With the launch of VeraBind™ Tau, Veravas introduces the first blood-based test to detect tau pathology, offering earlier, more accurate detection of Alzheimer’s and restoring confidence in diagnostics through sample purification technology.
In a recent feature on Startup+Health, Veravas CEO & Co-founder, John Forrest stated “We’re all about accuracy. Our technology isn’t just measuring something in the blood - it’s transforming the sample so that you’re not getting junk in, junk out. You’re getting truth in, truth out.”
MOMS is thrilled to be the Connection for the Collection™ for Veravas and helping increase access to testing nationwide for their patients.
Read more: Veravas Aims to Revolutionize Alzheimer’s Diagnostics with Groundbreaking Blood Test
